Professional Seasonal Analysis for Trading

Amneal Pharmaceuticals, Inc. - Class A Common Stock (AMRX)

Seasonality Analysis

Stocks 8 Years Analyzed

Amneal Pharmaceuticals, Inc. - Class A Common Stock Annual Seasonality Statistics

1.16%
Avg Annual Return
44.8%
Avg Monthly Win Rate
4/12
Positive Months
8
Years Analyzed

Amneal Pharmaceuticals, Inc. - Class A Common Stock Monthly Seasonality Performance

Month Avg Return Win Rate Strength
January -2.58%
38%
Very Weak
February -0.64%
50%
Weak
March -2.59%
38%
Very Weak
April 1.47%
38%
Weak
May BEST 6.75%
50%
Weak
June -2.83%
25%
Very Weak
July WORST -3.24%
50%
Weak
August 3.19%
63%
Strong
September -0.96%
25%
Very Weak
October -0.59%
50%
Weak
November -0.83%
50%
Weak
December 4.00%
63%
Strong

Amneal Pharmaceuticals, Inc. - Class A Common Stock 2026 vs Historical Pattern

Current Position
35.57
Historical Avg Position
37.29
Deviation
-1.73
Performance
On Track

Amneal Pharmaceuticals, Inc. - Class A Common Stock Interactive Seasonality Chart

Interactive Seasonality Chart

Unlock the full interactive seasonality chart for AMRX with overlay patterns, custom date ranges, and more.

Create Free Account

Amneal Pharmaceuticals, Inc. - Class A Common Stock Pattern Scanner

Pattern Scanner

Discover recurring patterns, anomalies, and statistically frequent setups.

Create Free Account

Amneal Pharmaceuticals, Inc. - Class A Common Stock Seasonal Historical Performance

Historical Performance

See historical average returns for AMRX across multiple timeframes.

Create Free Account

About Amneal Pharmaceuticals, Inc. - Class A Common Stock (AMRX) Seasonality

Amneal Pharmaceuticals, Inc. - Class A Common Stock (AMRX) has been analyzed using 8 years of historical data to identify seasonal patterns. Classified under Stocks, Amneal Pharmaceuticals, Inc. - Class A Common Stock shows distinct seasonal tendencies based on historical data.

The strongest month for Amneal Pharmaceuticals, Inc. - Class A Common Stock is historically May, with an average return of 6.75% and a win rate of 50%. Conversely, July tends to be the weakest month, averaging -3.24% return.

Looking at the full calendar year, Amneal Pharmaceuticals, Inc. - Class A Common Stock has an average annual return of 1.16% with an overall monthly win rate of 44.8%. Out of 12 months, 4 typically show positive average returns.

The seasonal pattern for Amneal Pharmaceuticals, Inc. - Class A Common Stock has a consistency score of 28.1 (Poor), based on 9 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.

Amneal Pharmaceuticals, Inc. - Class A Common Stock Seasonality FAQ

What is the best month to buy Amneal Pharmaceuticals, Inc. - Class A Common Stock (AMRX)?

Historically, May has been the best month for Amneal Pharmaceuticals, Inc. - Class A Common Stock, with an average return of 6.75% and a win rate of 50%. However, past performance does not guarantee future results.

What is the worst month for Amneal Pharmaceuticals, Inc. - Class A Common Stock (AMRX)?

Based on historical data, July has been the weakest month for Amneal Pharmaceuticals, Inc. - Class A Common Stock, with an average return of -3.24%. This is a historical observation and does not guarantee future results.

How reliable is AMRX seasonality data?

The seasonality analysis for Amneal Pharmaceuticals, Inc. - Class A Common Stock is based on 8 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.

How can I use Amneal Pharmaceuticals, Inc. - Class A Common Stock seasonality in my trading?

Use Amneal Pharmaceuticals, Inc. - Class A Common Stock (AMRX) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.

More Stocks Seasonality Analysis

Statistical information based on historical data. Does not constitute investment advice or recommendation. Past performance does not guarantee future results.